Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States.
Seoyoung C KimAmeet SarpatwariJoan E LandonRishi J DesaiPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2020)
Keyphrases